Dr. Dayan Goodenowe to present colorectal cancer associated GTAs study results

June 13, 2018

Dr. Dayan Goodenowe to present the results of Prodrome Sciences’ Japanese population distribution study of colorectal cancer associated gastrointestinal tract acids (GTAs) at the 59th Annual Scientific Meeting of Japan Society of Ningen Dock International

Prodrome Sciences Inc.’s Founder and CEO, Dr. Dayan Goodenowe, will present the results of Prodrome Sciences’ Japanese population distribution study of colorectal cancer associated gastrointestinal tract acids (GTAs) at the 59th Annual Scientific Meeting of Japan Society of Ningen Dock International on August 30, 2018, in Niigata, Japan.

Using Dr. Goodenowe’s patented high-resolution/accurate-mass technology, it was previously discovered that blood levels of certain ultra-long-chain fatty acids, called GTAs, are low in persons diagnosed with colorectal cancer. Over 90% of persons with colorectal cancer have low levels of GTAs in their blood. Low levels of GTAs in blood is a validated risk factor for colorectal cancer.

When the first GTA discoveries were made, it was not technologically feasible to commercialize the original multi-analyte, high-resolution/accurate-mass platform for routine applications. Because of the technological limitations, a single-analyte GTA test (GTA-446) was developed to represent the entire family of over 20 colorectal cancer associated GTAs. Prodrome Sciences has now overcome previous technological limitations with a new, commercial, high-resolution/accurate-mass technology platform. Prodrome Sciences’ new platform simultaneously measures multiple colorectal cancer associated GTAs in less than 2 minutes.

Prodrome Sciences’ new technology platform was used to evaluate the single-analyte GTA-446 as a representative of the entire family of GTAs. Blood levels of 18 GTAs with the strongest colorectal cancer associations (including GTA-446) were quantitated in over 3000 average risk Japanese persons aged 35-96. The results of the study indicate that using the single-analyte GTA-446 measurement to represent the entire family of colorectal cancer associated GTAs resulted in a significant number of false positive and false negative GTA-deficiency determinations. These false positive and false negative results were due to natural, individual, biological variability amongst the GTAs and not due to analytical variability. The results clearly indicate that a multi-analyte GTA test, as demonstrated in the original publications, is required to obtain an accurate determination of overall blood GTA levels associated with colorectal cancer. Detailed results will be presented at the conference.

Prodrome Sciences is an integrated molecular diagnostics and therapeutics company focused on the early detection and prevention of disease. The Company uses its patented comprehensive metabolomics technology to discover prodromes of diseases; prodromes are states of biochemical imbalance that occur before disease symptoms appear. Prodrome Sciences develops blood tests to detect prodromes of diseases and therapeutics to restore unhealthy biochemical imbalances to a healthy state. The goal is to reduce the number of people that develop and die from disease and to promote optimal health and longevity.

Please contact us for more information.

About Prodrome Sciences Inc.

Prodrome Sciences researches prodromes of diseases – how to detect them, what causes them, and how to return high-risk prodrome states back to a healthy state before the disease develops. We use our advanced diagnostic technology for blood tests to detect disease prodromes and in our natural therapeutic programs to restore an unhealthy, high-risk prodrome state to a healthy, low-risk state. Our goal is to reduce the number of people that develop and die from disease and to promote optimal health.

Keep in touch

©2018 Prodrome Sciences Inc.

Search